Anti-HLA-G Purified

Anti-HLA-G Purified
Regulatory status
RUO
Antigen
HLA-G
Clone
4H84
Format
Purified
Reactivity
Human
Variant
0.1 mg
11-499-C100
In stock
190.00 USD

0.025 mg
11-499-C025
In stock
95.00 USD
Variant
0.1 mg
11-261-C100
In stock
190.00 USD

0.1 mg
11-261-C100
In stock
95.00 USD
Product details
Description
Images
References
Isotype
Mouse IgG1
Specificity
The mouse monoclonal antibody 4H84 recognizes an extracellular epitope of HLA-G molecule (39 kDa). HLA-G belongs to the MHC Class I molecules (MHC Class Ib; nonclassical) and it is expressed on the surface of trophoblast cells.
Application details
Immunohistochemistry (paraffin sections): Recommended dilution: 10 μg/ml.
ELISA: The antibody 4H84 has been tested as the capture antibody in a sandwich ELISA for analysis of heavy chains of all HLA-G isoforms in combination with antibody MEM-G/1 (cat. no. 1B-291-C100).
Western blotting: Recommended dilution 1-2 μg/ml.
Reactivity
Human
Immunogen
amino acids 61-83 of HLA-G of human origin
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography.
Formulation
Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Licence notice
This product is for research and in vitro experimental use only. It is not to be used for any other commercial purpose. Use of this product to produce products for sale or for therapeutic or drug discovery purposes is prohibited. In order to obtain a license to use this product for commercial purposes, contact The Regents of the University of California.
Antigen description
Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage.
Entrez Gene ID 3135
UniProt ID P17693
11-499_WB
Western blotting analysis of human HLA-G using mouse monoclonal antibody 4H84 on lysates of JEG-3 cell line and LNCaP cell line (negative control) under reducing and non-reducing conditions. Nitrocellulose membrane was probed with 2 µg/ml of mouse monoclonal antibody anti-HLA-G followed by IRDye800-conjugated anti-mouse secondary antibody. HLA-G was detected at approximately 40 kDa.
11-499_IHC
Immunohistochemistry staining of human spleen (paraffin sections) using anti-HLA-G (4H84). Commercially tested by LifeSpan BioSciences.
11-499 IP
Immunoprecipitation of HLA-G from HLA-G1 transfectants (LCL-HLA-G1) by MEM-G/9 antibody and protein G. HLA-G was detected by 4H84 antibody and goat anti-mouse-HRP conjugate in cell lysate (Lane 1) and in the immunoprecipitate (Lane 2).

General references:

Creput C, Durrbach A, Menier C, Guettier C, Samuel D, Dausset J, Charpentier B, Carosella ED, Rouas-Freiss N. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol. 2003 39(4):587-94.
PubMed
Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, LeDanff C, Reboul M, Hilgert I, Rabreau M, Larrad ML, Pla M, Carosella ED, Rouas-Freiss N: Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol. 2003 64(3):315-26.
PubMed
Lin A, Yan WH: Heterogeneity of HLA-G expression in cancers: Facing the challenges. Front Immunol. 2018 Sep 27;9:2164.
PubMed
Hunt JS, Langat DK, McIntire RH, Morales PJ: The role of HLA-G in human pregnancy. Reprod Biol Endocrinol. 2006;4 Suppl 1(Suppl 1):S10.
PubMed
Xu HH, Yan WH, Lin A: The role of HLA-G in human papillomavirus infections and cervical carcinogenesis. Front Immunol. 2020 Jun 25;11:1349.
PubMed
Castelli EC, de Almeida BS, Muniz YC, Silva NS, Passos MR, Souza AS, Page AE, Dyble M, Smith D, Aguileta G, Bertranpetit J, Migliano AB, Duarte YA, Scliar MO, Wang J, Passos-Bueno MR, Naslavsky MS, Zatz M, Mendes CT, Donadi EA: HLA-G genetic diversity and evolutive aspects in worldwide populations. Sci Rep. 2021 Nov 29;11(1):23070.
PubMed
Curigliano G, Criscitiello C, Gelao L, Goldhirsch A: Molecular pathways: Human leukocyte antigen G (HLA-G). Clin Cancer Res. 2013 Oct 15;19(20):5564-71.
PubMed

Product specific references:

Blaschitz A, Hutter H, Dohr G: HLA Class I protein expression in the human placenta. Early Pregnancy. 2001 Jan;5(1):67-9.
PubMed
Urosevic M, Kurrer MO, Kamarashev J, Mueller B, Weder W, Burg G, Stahel RA, Dummer R, Trojan A: Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol. 2001 Sep;159(3):817-24.
PubMed
Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, Le Danff C, Reboul M, Hilgert I, Rabreau M, Larrad ML, Pla M, Carosella ED, Rouas-Freiss N: Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol. 2003 Mar;64(3):315-26.
PubMed
Polakova K, Krcova M, Kuba D, Russ G: Analysis of HLA-G expression in malignant hematopoetic cells from leukemia patients. Leuk Res. 2003 Jul;27(7):643-8.
PubMed
Polakova K, Kuba D, Russ G: The 4H84 monoclonal antibody detecting beta2m free nonclassical HLA-G molecules also binds to free heavy chains of classical HLA class I antigens present on activated lymphocytes. Hum Immunol. 2004 Feb;65(2):157-62.
PubMed
Juch H, Blaschitz A, Daxbock C, Rueckert C, Kofler K, Dohr G: A novel sandwich ELISA for alpha1 domain based detection of soluble HLA-G heavy chains. J Immunol Methods. 2005 Dec 20;307(1-2):96-106.
PubMed
Barrier BF, Kendall BS, Sharpe-Timms KL, Kost ER: Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecol Oncol. 2006 Oct;103(1):25-30.
PubMed
Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED: HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4510-5.
PubMed
Gonen-Gross T, Achdout H, Arnon TI, Gazit R, Stern N, Horejsí V, Goldman-Wohl D, Yagel S, Mandelboim O: The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and beta 2-microglobulin-free HLA-G molecules. J Immunol. 2005 Oct 15;175(8):4866-74.
PubMed
Creput C, Le Friec G, Bahri R, Amiot L, Charpentier B, Carosella E, Rouas-Freiss N, Durrbach A: Detection of HLA-G in serum and graft biopsy associated with fewer acute rejections following combined liver-kidney transplantation: Possible implications for monitoring patients. Hum Immunol. 2003 Nov;64(11):1033-8.
PubMed
Poláková K, Bennink JR, W Yewdell J, Bystrická M, Bandzuchová E, Russ G: Mild acid treatment induces cross-reactivity of 4H84 monoclonal antibody specific to nonclassical HLA-G antigen with classical HLA class I molecules. Hum Immunol. 2003 Feb;64(2):256-64.
PubMed
Zhang X, Lin A, Han QY, Zhang JG, Chen QY, Ye YH, Zhou WJ, Xu HH, Gan J, Yan WH: Intratumor heterogeneity of HLA-G expression in cancer lesions. Front Immunol. 2020 Nov 19;11:565759.
PubMed
Variant
0.1 mg
11-499-C100
In stock
190.00 USD

0.025 mg
11-499-C025
In stock
95.00 USD
Variant
0.1 mg
11-261-C100
In stock
190.00 USD

0.1 mg
11-261-C100
In stock
95.00 USD